Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [5][18]. Core Views - The company is experiencing a performance recovery that exceeds expectations, with growth potential still present in the mid-term [1]. - The recovery in the cottonseed business is a significant factor contributing to the strong performance in the first half of the year, supported by favorable market conditions [2]. - The company is positioned as a leader in the plant extract sector, with stable profitability from key products and a strategic plan that is progressing steadily [9]. Financial Summary - **Revenue Forecast**: The company expects to achieve revenues of 6,872 million yuan in 2023, with a growth rate of 9.1%. Projections for 2024 and 2025 show revenues of 6,994 million yuan and 7,064 million yuan, respectively, with growth rates of 1.8% and 1.0% [1]. - **Net Profit**: The forecasted net profit for 2023 is 480 million yuan, with a year-on-year growth of 10.5%. However, a significant drop is expected in 2024, with a projected net profit of 94 million yuan, reflecting an 80.4% decline. A recovery is anticipated in 2025, with a net profit of 346 million yuan, representing a growth of 268.1% [1]. - **Earnings Per Share (EPS)**: The latest diluted EPS is projected to be 0.99 yuan in 2023, dropping to 0.19 yuan in 2024, and recovering to 0.72 yuan in 2025 [1][9]. - **Price-to-Earnings (P/E) Ratio**: The P/E ratio is expected to be 13.7 in 2023, soaring to 70.0 in 2024, and then stabilizing at 19.0 in 2025 [1][9]. Market Conditions - The cottonseed market is showing a stable upward trend, which has positively impacted the company's performance in the first half of the year [2]. - The company is expected to benefit from multiple growth drivers, including increased product volume, improved efficiency in overseas plantations, and a growing demand for health products [2].

Q2 业绩超预期，棉籽持续回暖，植提业务向好。单25Q2 看，预计公司营业收入为17.44-20.44 亿元， 同比-0.9%至+16.2%，预计公司归母净利润为0.93-1.23 亿元，同比+51.1%至+100.1%，预计公司扣非归 母净利润为0.78-1.08 亿元，同比+147.5%至+242.6%。25H1 棉籽类业务行情回暖，公司严格执行对锁经 营模式，同比实现扭亏为盈；植提类业务中，辣椒红、辣椒精、甜菊糖苷等植提类业务毛利润均实现同 比增长，植提呈现向好趋势 短期看棉籽业务盈利修复，中长期植提业务景气度向上。棉籽业务方面，25 年，公司在严格执行对锁 经营模式的情况下，锁定了加工环节的利润，全年盈利改善的趋势较强；植提业务方面，当前多个植提 产品价格处于相对低位，有望逐渐企稳向好，25 年4 月，美国FDA 宣布计划将于26 年底前逐步停止使 用石油基合成的食品色素，我们认为美国FDA 此举将有望推动全球人工色素的加速淘汰，天然色素占 比将提升，推动公司的辣椒红、叶黄素、番茄红素等天然色素的需求增长，植提业务的毛利率有望提 升。 盈利预测与投资评级：公司作为植物提取物龙头企业，植提技术行业领先， ...

内容概要：桑叶提取物是从桑树叶片中提取的活性成分，富含多种生物活性物质。得益于桑叶的药用和 保健价值被不断挖掘，以及国内外市场对天然植物提取物需求的增长，我国桑叶提取物行业近年来发展 迅速。我国是全球桑叶资源最丰富的国家之一，产业链从种桑养蚕延伸到高附加值提取物，形成了一定 规模。2024年，国内桑叶提取物市场规模19917万元，行业产值27658万元，产能834吨，产量563吨，需 求量411.5吨；预计2025年，我国桑叶提取物市场规模将达21765万元，行业产值将达30065万元，产能 将达892吨，产量将达598.4吨，需求量将达439.7吨。随着桑叶提取物在医药、食品、保健品等领域的应 用不断扩大，市场规模将逐年增长。特别是随着功能性食品的兴起和消费者对天然、健康产品的需求增 加，桑叶提取物作为天然、健康的添加剂，市场潜力巨大。桑叶提取物细分市场将呈现多元化与专业化 并行的发展态势。 二、桑叶提取物行业发展现状 上市企业：莱茵生物（002166） 桑叶在中国种植历史悠久，不仅具有较高的经济价值、药用价值，也具有一定的食用价值，是优良的食 药同源作物。我国桑树资源丰富，为桑叶提取物行业提供了坚实的原料 ...

证券代码：833230 证券简称：欧康医药 公告编号：2025-045 成都欧康医药股份有限公司 □分析师会议 □路演活动 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □其他 二、 投资者关系活动情况 活动时间：2025 年 4 月 29 日（周二）15:00-16:00 活动地点：公司 2024 年年度报告业绩说明会于 2025 年 4 月 29 日（周二） 15:00-16:00 在上海证券报·中国证券网（https://roadshow.cnstock.com）举行，通 过网络方式与投资者进行了沟通和交流。 参会单位及人员：通过网络方式参与公司 2024 年年度报告业绩说明会的投 资者。 上市公司接待人员：公司董事长、总经理：赵卓君先生；公司董事会秘书、 财务负责人：曹永强先生；公司保荐代表人：罗泽先生。 三、 投资者关系活动主要内容 公司在 2024 年年度业绩说明会上就投资者 ...

Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit and earnings per share, indicating strong operational efficiency and profitability despite revenue challenges [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 1.716 billion yuan, a year-on-year decrease of 0.9% [1]. - The net profit attributable to shareholders was 109 million yuan, reflecting a year-on-year increase of 183.7% [1]. - Basic earnings per share (EPS) reached 0.2266 yuan, up 212.6% year-on-year [1]. Business Segment Analysis - The cottonseed business has returned to normal operations, while the plant extraction business has exceeded expectations [2]. - The plant extraction segment generated revenue of 867 million yuan, a year-on-year increase of 13.8%, with a gross margin improvement of 2.15 percentage points [2]. - The cottonseed segment reported revenue of 760 million yuan, a year-on-year decrease of 9.5%, with a gross margin of approximately 6.1% [2]. Market Strategy - The company adopted a strategy of "price for volume," leading to increased sales volume and revenue growth in various product lines [3]. - The price of chili red pigment significantly decreased, resulting in a revenue increase of approximately 7% due to volume elasticity [3]. - The company capitalized on domestic raw material cost advantages to expand into overseas markets, with chili extract sales doubling and contributing to a revenue increase of about 24% [3]. Long-term Outlook - The company is focused on long-term advantages, expanding overseas planting bases, and making breakthroughs in new businesses such as traditional Chinese medicine and health products [3]. - The company anticipates maintaining high growth rates in performance as major products return to a cyclical uptrend [3]. Investment Recommendation - The company is a leading player in the plant extract sector, with stable profitability in key products and a strong growth trajectory in market share [4]. - The ongoing construction of the Zambia plantation is expected to further reduce costs, and the health product business shows significant potential for growth [4]. - Projected EPS for 2025-2027 is 0.67, 0.83, and 1.00 yuan, with corresponding price-to-earnings ratios of 16.3X, 13.1X, and 10.9X, maintaining a "buy" rating [4].

近年来,青少年近视已成为全球公共卫生问题。我国作为近视高发地区,儿童青少年总体近视率超过50%, 高度近视引发的视网膜病变风险更令人担忧。在现有的防控手段中,0.01%低浓度阿托品滴眼液虽被广泛 使用,但其对眼轴增长的控制效果有限。而一项来自日本的突破性研究发现,天然植物提取物藏红花酸 (Crocetin)不仅能够延缓眼轴增长,还能显著增厚脉络膜,为近视防控开辟了新路径。 一、现有近视防控的困境:阿托品的局限 低浓度阿托品通过麻痹睫状肌放松调节,能有效延缓近视度数增长(约60%控制率),但其对眼轴的控制效果 (约30%)却明显不足。研究发现,这种差异源于阿托品的双重作用: 1. 验光偏差:其扩瞳作用可能导致验光度数测量值偏低; 2. 代偿效应:长期使用会诱导晶状体变薄,通过屈光力下降对冲眼轴增长的影响 这意味着,即便近视度数看似稳定,眼球的病理性拉长仍在持续,而眼轴每增长1mm,近视度数加深约 200~300度,视网膜脱离风险也随之升高。因此,寻找能直接抑制眼轴增长的干预手段迫在眉睫。 二、藏红花酸的发现:从分子筛选到动物验证 2018年,日本研究团队在《自然·眼科研究》发表了一项开创性研究。他们从207种天 ...

甜菊糖苷目前已成为饮料行业减糖转型的核心原料，在无糖茶饮、碳酸饮料、果汁等品类中渗透率逐步 提升。2024年底，国家卫健委发布了《关于金花茶培养物等11种"三新食品"的公告》，批准甜菊糖苷扩 大使用范围，包括乳粉、干酪、方便米面制品等多个品类。目前甜菊糖苷在国内作为广受认可的食品添 加剂，已扩展至二十余类食品领域;另外，由于甜菊糖苷具备不升糖、抗氧化、抗炎等特性，使其在医 药与保健品领域的应用也逐步得到延伸，用于糖尿病辅助治疗、降血压等药物和保健类产品中。 4月25日晚间，莱茵生物(002166.SZ)披露2025年一季度报告。报告期内，莱茵生物紧紧围绕主营业 务"双技术路线、双供应链路、多产品共发展"的核心经营策略，全力推动海外供应链的优化与业务结构 的调整、合成生物技术的商业化进程，以及配方应用研发等重点项目的实施。2025年一季度公司实现营 业收入4.44亿元，同比增长30.21%;实现归母净利润3,079.49万元，同比增长14.95%。 报告期内，莱茵生物坚定落实"大单品+N"的产品战略，以天然甜味剂产品为核心，搭建覆盖食品饮 料、医药保健、日化美妆、动物饲料等多元化下游应用的产业生态圈。 罗汉果提 ...